Chadbourne Wins Patent Office Victory for Synthon in Pexeva Case
Chadbourne & Parke LLP recently represented Synthon Pharmaceuticals, Ltd. in a victory in its patent interference case in the U.S. Patent and Trademark Office over GlaxoSmithKline.
Synthon launched Pexeva this year in competition with GSK’s top-selling antidepressant Paxil®. On May 25, the Patent Office ruled that Synthon has sole rights to the patent on its drug and denied GSK’s claim for patent protection.
Last Dec. 30, Chadbourne won a settlement for Synthon right before a scheduled trial in a patent infringement lawsuit brought by GlaxoSmithKline. That settlement, coming on the eve of a January 12th trial date in federal court in Greensboro, NC, paved the way for the Chapel Hill, NC drug maker to begin selling Pexeva™, its competitor to GSK’s antidepressant medication Paxil®.
As in the court case, Chadbourne partner Mark Waddell was lead counsel for Synthon in the U.S. Patent Office case. He was assisted by Chadbourne associates Kathleen Gersh and Kimberly Muller.
